A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: 23-PPV
BIOLOGICAL: 13-PCV Booster
BIOLOGICAL: Influenza Vaccine
BIOLOGICAL: KLH
DRUG: OCR
BIOLOGICAL: TT Vaccine

Sponsor

Hoffmann-La Roche